Globally, breast cancer is both the most common cancer and the most common cause of death related to cancer among women. It is estimated that over 2 million women were diagnosed with breast cancer in 2022 worldwide, while almost 400,000 were diagnosed in the EU. Breast cancer has different histopathological subtypes that require different therapeutic approaches. Triple-negative breast cancer (TNBC) is a type that is considered more aggressive; it occurs in about 10 to 20% of all breast cancer cases. Approximately 40% of women initially diagnosed with TNBC will develop metastases. The objective of this study is to present current clinical trials focused on new treatment of advanced and metastatic TNBC. The study was conducted by searching the clinicaltrials.gov database. Due to the scope of this paper, primary endpoints in the included studies were objective response rate, treatment-emergent adverse events or serious adverse events, progression-free survival, and probability of pathologic complete response. Some of the selected studies were phase I or II RCTs; therefore, we should carefully examine their future results and implications for clinical guidelines.
在全球范围内，乳腺癌既是女性最常见的癌症，也是女性癌症相关死亡的首要原因。据估计，2022年全球有超过200万女性被诊断出乳腺癌，其中欧盟地区约有40万例。乳腺癌具有不同的组织病理学亚型，需要采取不同的治疗方法。三阴性乳腺癌（TNBC）是一种被认为更具侵袭性的类型，约占所有乳腺癌病例的10%至20%。约40%初次诊断为TNBC的女性患者会出现转移。本研究旨在介绍当前针对晚期和转移性TNBC新疗法的临床试验。研究通过检索clinicaltrials.gov数据库进行。鉴于本文的研究范围，纳入研究的主要终点包括客观缓解率、治疗中出现的不良事件或严重不良事件、无进展生存期以及病理完全缓解概率。部分入选研究为I期或II期随机对照试验，因此我们需审慎评估其未来结果及对临床指南的影响。
Advanced and Metastatic Triple Negative Breast Cancer—Potential New Treatment
肿瘤(癌症)患者之家